For the quarter ended September 2025, Integer (ITGR) reported revenue of $467.69 million, up 8.4% over the same period last year. EPS came in at $1.79, compared to $1.43 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $465.78 million, representing a surprise of +0.41%. The company delivered an EPS surprise of +6.55%, with the consensus EPS estimate being $1.68.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Integer performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Sales- Medical Sales- Other Markets: $21.39 million versus the four-analyst average estimate of $16.91 million.
- Sales- Medical Sales- Cardio & Vascular: $277.15 million compared to the $272.08 million average estimate based on four analysts. The reported number represents a change of +15% year over year.
- Sales- Medical Sales- Cardiac Rhythm Management & Neuromodulation: $169.16 million versus $176.66 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +2.5% change.
View all Key Company Metrics for Integer here>>>
Shares of Integer have returned +6% over the past month versus the Zacks S&P 500 composite's +0.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Integer Holdings Corporation (ITGR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
